天美生物股价窄幅波动，2025财年业绩亏损扩大

Group 1 - The stock price of Tianmei Biotech (BON.OQ) closed at $1.63 as of February 12, 2026, with a 7-day price fluctuation of 0.00%, indicating low market interest [1] - The stock traded within a narrow range of $1.58 to $1.68, with a volatility of 6.13%, and a total trading volume of 77,562 shares over the week, averaging about $18,000 per day [1] - Compared to the broader market, where the Dow Jones increased by 2.61% and the Nasdaq by 1.61%, the chemical products sector, to which Tianmei belongs, only saw a slight increase of 0.37%, highlighting the company's underperformance [1] Group 2 - For the fiscal year 2025 ending September 30, 2025, Tianmei Biotech reported a revenue of $18.67 million, a year-on-year decline of 21.70% [2] - The company experienced a net loss of $1.995 million, which represents a significant increase in losses by 577.58%, resulting in a net profit margin of -10.68% [2] - The gross margin stood at 20.77%, but operational efficiency was low, with an asset turnover ratio of only 0.25 times, and free cash flow was negative at -$4.23 million [2] - The debt-to-asset ratio was 31.92%, and the current ratio was 1.74, indicating adequate solvency, but the company's profitability and growth potential appear weak, with insufficient fundamental support [2]